These smaller population “Orphan Diseases,” defined as those that affect less than 200,000 people across the U.S., collectively impact 25 million Americans. This substantial public health issue warrants Lancet's call-to-action.
Society often pathologizes normal development. When this is done, a medicine must be made for treatment (needed or not). The FDA recently called out a group of over-the-counter drugs for being harmful and without benefit for infant teething.
Commissioner Scott Gottlieb believes that his FDA should be in the business of getting smokers to transition away from cigarettes, to something less harmful like e-cigarettes or other products. That's similar to the policy taken by the UK's National Health Service, and it's precisely in line with ACSH's policy stance of harm reduction.
It is Game On! for President Trump appointee Scott Gottlieb, the commissioner of the Food and Drug Administration. Things are definitely changing there, and at this point, it's a pretty good start.
Due to the opaque nature of the pharmaceutical industry’s disclosures, a study published in JAMA Internal Medicine sought to quantify a standard amount companies spent on the research and development of cancer drugs. Do these R&D costs justify such high prices and revenues?
Who hasn’t chuckled at a TV prescription drug ad, during its litany of wide-ranging potential side effects? Anal leakage and the oft-repeated erections lasting more than four hours? With direct-to-consumer marketing, product overstatements of health benefits with simultaneous minimization of possible harms have become the norm. Now, the FDA wants to change that.